E d i t o r i a l Let's Not Ignore the Statistics
In a Nature News Feature entitled 'The Hard Copy', Erika Check asked why some stem cell studies are so notoriously difficult to replicate [1] . While conflicting findings are often explained away by differences in experimental conditions, it is nevertheless worrying if research effort is being wasted on false trails. Such concerns recently surfaced to public scrutiny in the Washington Post ('When Science is a Siren Song', March 14, 2009 ) in which John Iaonnidis of Tufts University was cited, trenchantly claiming that ''false findings may be the majority or even the vast majority of published research claims'' [2] . Even if this is an exaggeration, the implications are alarming for scientists and science policy because we implicitly trust results that have triumphed after peer-review. He attributes the problem to placing too much confidence in single studies assessed by formal statistical significance (typically P-value , 0.05).
In an ideal world where time and resources are unlimited every new discovery would be verified independently, but this is only realistic when claims are sufficiently important that they affect the development of a field. Sometimes observed effects (particularly small ones) can be reasonably attributed to chance variation instead of some underlying cause, and a robust study design and proper statistical analysis are chief safeguards against misleading conclusions.
The current controversy about oogenesis in adult mammalian ovaries, highlighted in a recent Minireview [3] , is an example of how exciting new findings challenging an existing theory might be based on spurious results. This is no arcane debate because the doctrine that follicles are not renewed after birth has underpinned the physiology of oocyte biology, ovarian aging and menopause for six decades, influencing clinical practice [4] . Over the years virtually every study has observed highly variable numbers of ovarian follicles between animals of the same age and genetic strain [5] [6] [7] [8] [9] [10] , as illustrated in Supplemental Figure S1 (available online at www.biolreprod.org) from this journal. This enormous variation, which is largely biological rather than from counting errors, can result in apparent (and sometimes quite large) effects being due to chance alone. We have therefore re-examined some of the data responsible for stimulating the controversy about ovarian regeneration to test conclusions, and to illuminate the importance of critical statistical analysis of experimental data.
The original paper [11] that sparked the controversy contained data on follicle counts in postnatal C57BL/6J mouse ovaries which were interpreted as evidence of follicle replacement. We found from linear regression analyses that there is significant (P-values , 0.02) evidence from these data of an overall decrease in both mean total and primordial follicle numbers with increasing age. There were some apparent anomalies in the data where the observed means showed some increase from 4 to 8 days and from 16 to 20 days of age, suggesting that new follicles might be being formed. However, none of these differences was statistically significant (P-values . 0.20). Neither was there any significant (P-value . 0.20) evidence of an increase in mean nonatretic follicle numbers based on a similar analysis of another strain (AKR/J) between Postnatal Days 4 and 42.
In a comparable study [12] , there was no significant (P-values . 0.20) evidence of any increase or decrease in either mean total or primordial follicle numbers between 7 and 100 days of age. These data are thus uninformative about follicle renewal or depletion, despite the authors claiming that their data gave ''qualified support for an as yet unknown mechanism for follicle renewal''.
Another paper [13] claimed that ''spontaneous regeneration of the immature follicle pool was observed between 24 and 36 h posttreatment'' with doxorubicin. Analysis of variance of the data does show highly significant (P-value ' 0.001) overall differences between the mean follicle counts at times 0, 12 h, 24 h, 36 h, 48 h, 120 h and 2 mo posttreatment. However, subsequent multiple comparisons of temporally adjacent means with an adjustment of the significance level to allow for the six possible comparisons here shows that the only significant difference is between the means at times 12 and 24 h posttreatment -i.e., the effect of the doxorubicin treatment. The evidence for any difference between 24 and 36 h posttreatment is not significant (P-value ' 0.16, after Bonferroni adjustment).
The lack of any significant increases in mean follicle numbers from these studies despite observed magnitudes of 20% or more could be due to there being no actual increase in mean follicle numbers (i.e., consistent with conventional theory [4] ) and/or to the low replication levels (n ¼ 3-8 mice per group) not being high enough for the statistical methods to have sufficient power. Taking the AKR/J strain data [11] as an example, the level of replication used would have 90% power of inferring some net increase in mean follicle numbers at 5% significance only if the actual increase in mean follicle numbers were quite high -45 or more additional follicles per day.
None of the reliable data on follicle numbers that we are aware of is inconsistent with declines in mean total and primordial numbers with increasing age, and the new data [11] [12] [13] are no exception. Nor is this conclusion necessarily inconsistent with claims that stem cells exist in postnatal ovaries with germline potential under experimental conditions [14] . Whilst it is undoubtedly true that absence of evidence is not evidence of absence [3] , the inference that total and primordial follicle numbers behave postnatally as if there is no renewal and only depletion would seem entirely reasonable. This would make us ovarian pessimists [3] 
